BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaBusiness Wire • 02/29/24
BeiGene's Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDABusiness Wire • 02/27/24
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesBusiness Wire • 02/26/24
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung CancerBusiness Wire • 02/26/24
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of DirectorsBusiness Wire • 01/23/24
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)Business Wire • 12/22/23
Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a BetZacks Investment Research • 11/30/23
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023Business Wire • 11/29/23
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023Business Wire • 11/28/23
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 InhibitorBusiness Wire • 11/21/23
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness Wire • 11/17/23
Wall Street Analysts Believe BeiGene, Ltd. (BGNE) Could Rally 32.87%: Here's is How to TradeZacks Investment Research • 11/14/23
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business UpdatesBusiness Wire • 11/09/23
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic LeukemiaBusiness Wire • 10/20/23
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction AdenocarcinomaBusiness Wire • 10/17/23
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)Business Wire • 10/17/23